Your session is about to expire
← Back to Search
Lymphedema Prevention Strategies
N/A
Waitlist Available
Led By Simona Shaitelman
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is to see how breast cancer patients feel about being screened for lymphedema, and if they're happy with the program.
Who is the study for?
The PREVENT trial is for English-speaking breast cancer patients who've had axillary lymph node dissection. It includes those with preoperative measurements (Cohort I) and those within 0-6 months post-surgery intending to continue follow-up at MD Anderson (Cohort II). Patients unable to complete a questionnaire are excluded.
What is being tested?
This study evaluates patient opinions on lymphedema screening, which detects swelling after breast cancer treatment. Cohort I receives annual screenings, while Cohort II has more intensive follow-ups. Patient satisfaction with the program is also assessed.
What are the potential side effects?
Since this trial focuses on screening and opinion gathering rather than medical intervention, it does not directly involve side effects from treatments or medications.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Cohort II (patients followed intensively for lymphedema)Experimental Treatment1 Intervention
We will prospectively follow a cohort of 279 patients who have recently undergone ALND in this upcoming year with intensive lymphedema screening.
Group II: Cohort I (patients receiving annual lymphedema screening)Experimental Treatment1 Intervention
We will retrospectively retrieve information on patients who previously underwent preoperative perometer lymphedema screening during the past year who were treated definitively for their breast cancer with an ALND, and for whom no follow-up postoperative lymphedema screening was done.
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
3,063 Previous Clinical Trials
1,800,521 Total Patients Enrolled
Simona ShaitelmanPrincipal InvestigatorM.D. Anderson Cancer Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I had surgery to remove lymph nodes due to breast cancer and visited the Nellie B. Connally Breast Center about a year later.I had breast cancer surgery with lymph node removal and plan to follow up at MD Anderson within 6 months.I am a breast cancer patient who has had surgery to remove lymph nodes under my arm.
Research Study Groups:
This trial has the following groups:- Group 1: Cohort II (patients followed intensively for lymphedema)
- Group 2: Cohort I (patients receiving annual lymphedema screening)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger